Clinical Pharmacology Group Head - Anti-infectives, Early Clinical Development
Pfizer
Groton, Connecticut
Art Bergman is Clinical Pharmacology Group Head for Anti-Infectives, Early Clinical Development at Pfizer, Inc. In this role, Art was the early clinical research project team leader for the Paxlovid development program. Art has greater than 20 years of experience in the pharmaceutical industry and has supported development programs across the gamut of the clinical development spectrum ranging from preclinical stages to post-marketing support. Art’s areas of interest include designing phase 1 development strategies that integrate understanding of target engagement along with PK, safety and tolerability assessments to quantitatively inform design of phase 2 and 3 clinical studis, including patient and dose selection. Art is an advocate for model informed drug development, leveraging traditional PK/PD modeling, semi-mechanistic, quantitative systems pharmacology models and model-based meta analysis, as appropriate, to inform expected clinical response, study design and programmatic decisions.
Disclosure information not submitted.
Monday, October 17, 2022
3:00 PM – 3:15 PM ET